What is CeQur?
Headquartered in Switzerland, CeQur is dedicated to the commercialization of advanced, simple-to-use insulin-delivery devices. Since its inception in 2008, the firm has focused on bridging the gap between complex medical technology and the daily needs of patients living with diabetes. By prioritizing ease of use and therapeutic control, CeQur aims to mitigate the challenges associated with traditional insulin administration. The company operates at the intersection of healthcare innovation and patient-centric design, positioning itself as a critical contributor to the modernization of chronic disease management systems.
How much funding has CeQur raised?
CeQur has raised a total of $491.6M across 5 funding rounds:
Series A
$29.6M
Series B
$27M
Series C
$215M
Private Equity
$120M
Series E
$100M
Series A (2010): $29.6M with participation from Endeavour Vision and VI Partners
Series B (2013): $27M, investors not publicly disclosed
Series C (2015): $215M supported by Ypsomed, VI Partners, Tandem Diabetes Care, GMS Capital, Kingdon Capital Management, Endeavour Vision, Federated Hermes Kaufmann Funds, Credit Suisse, Arthurian Life Sciences, Woodford Investment Management, and Bank of Communications Schroder Fund Management Co. Ltd.
Private Equity (2025): $120M, investors not publicly disclosed
Series E (2026): $100M, investors not publicly disclosed
Key Investors in CeQur
Endeavour Vision
Endeavour Vision is a leading investment advisory firm specializing in transformative healthcare technologies, particularly in medical devices and digital health.
VI Partners
VI Partners is the longest-established Swiss VC firm, supporting innovative healthcare and technology companies for over two decades.
Woodford Investment Management
Woodford Investment Management is a financial services firm that managed various investment funds, including the Woodford Patient Capital Trust.
What's next for CeQur?
With the infusion of this latest capital, CeQur is well-positioned to accelerate its commercial expansion and deepen its market penetration. The strategic focus will likely shift toward scaling manufacturing capabilities and broadening the distribution of its flagship devices to meet international demand. Furthermore, the company is expected to leverage these resources to enhance its clinical research initiatives, ensuring that its product pipeline remains at the forefront of medical device innovation. As CeQur continues to navigate the complexities of the global healthcare market, this funding provides the necessary runway to sustain its mission of empowering patients through superior technology and improved disease management protocols.
See full CeQur company page
